She added in a telephone interview yesterday that an extension of the study is under way, and researchers expect to report to the FDA in late fall.
"Physicians, will, for a time, be forced to make their professional judgments about aspirin use on the basis of incomplete information," said the FDA commentary, co-written by agency Director Dr. Frank E. Young.
The FDA commentary pointed to 10 hemorrhagic strokes recorded among the 11,000 subjects taking aspirin in the recent study, compared with two such strokes among 11,000 subjects taking the substitute.
A study published in January indicated an aspirin every other day reduced the risk of nonfatal, first heart attacks 47% in 11,000 male doctors over five years, compared with 11,000 who took a non-aspirin substitute.
